<!DOCTYPE html>
<html lang="de">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cholesterin-/Steroid-Biosynthese - Teil 2A</title>
    <style>
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary-color: #8b5cf6;
            --secondary-color: #ec4899;
            --accent-color: #06b6d4;
            --success-color: #10b981;
            --warning-color: #f59e0b;
            --danger-color: #ef4444;
            --info-color: #3b82f6;
            --text-primary: #1f2937;
            --text-secondary: #4b5563;
            --text-muted: #6b7280;
            --bg-white: #ffffff;
            --bg-light: #f8fafc;
            --bg-lighter: #f1f5f9;
            --border-radius: 16px;
            --border-radius-lg: 24px;
            --spacing-xs: 8px;
            --spacing-sm: 16px;
            --spacing-md: 24px;
            --spacing-lg: 32px;
            --spacing-xl: 48px;
            --shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            --shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
            --shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }
        
        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
            min-height: 100vh;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: var(--spacing-md);
        }
        
        /* Header */
        .header {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
        }
        
        .header h1 {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color), var(--accent-color));
            background-size: 200% 200%;
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: clamp(2rem, 5vw, 3.5rem);
            font-weight: 700;
            margin-bottom: var(--spacing-sm);
            animation: gradientShift 4s ease-in-out infinite;
        }
        
        @keyframes gradientShift {
            0%, 100% { background-position: 0% 50%; }
            50% { background-position: 100% 50%; }
        }
        
        .header p {
            color: var(--text-secondary);
            font-size: 1.3rem;
            font-weight: 400;
        }
        
        /* Progress bar */
        .progress-container {
            background: var(--bg-lighter);
            border-radius: 50px;
            height: 10px;
            margin-top: var(--spacing-md);
            overflow: hidden;
        }
        
        .progress-fill {
            background: linear-gradient(90deg, var(--primary-color), var(--accent-color));
            height: 100%;
            border-radius: 50px;
            transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
            position: relative;
            overflow: hidden;
        }
        
        .progress-fill::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
            animation: progressShimmer 2s infinite;
        }
        
        @keyframes progressShimmer {
            0% { transform: translateX(-100%); }
            100% { transform: translateX(100%); }
        }
        
        /* Navigation */
        .navigation {
            background: var(--bg-white);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            display: flex;
            flex-wrap: wrap;
            gap: var(--spacing-sm);
            justify-content: center;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .nav-btn {
            background: var(--bg-light);
            border: 2px solid #e2e8f0;
            color: var(--text-primary);
            padding: 16px 24px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 14px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .nav-btn:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
            border-color: var(--primary-color);
        }
        
        .nav-btn.active {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            border-color: var(--primary-color);
            box-shadow: var(--shadow-md);
        }
        
        /* Content sections */
        .content-section {
            background: var(--bg-white);
            border-radius: var(--border-radius-lg);
            padding: var(--spacing-xl);
            margin-bottom: var(--spacing-lg);
            box-shadow: var(--shadow-md);
            border: 1px solid #e2e8f0;
            display: none;
        }
        
        .content-section.active {
            display: block;
            animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
        }
        
        @keyframes slideInUp {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .section-title {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: var(--spacing-lg);
            position: relative;
            padding-bottom: var(--spacing-sm);
        }
        
        .section-title::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 4px;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            border-radius: 2px;
            animation: expandWidth 0.8s ease-out 0.3s both;
        }
        
        @keyframes expandWidth {
            from { width: 0; }
            to { width: 60px; }
        }
        
        /* Subsections */
        .subsection {
            margin-bottom: var(--spacing-lg);
            padding: var(--spacing-lg);
            background: var(--bg-light);
            border-radius: var(--border-radius);
            border: 1px solid #e2e8f0;
            transition: all 0.3s ease;
        }
        
        .subsection:hover {
            transform: translateY(-2px);
            box-shadow: var(--shadow-md);
            background: var(--bg-white);
        }
        
        .subsection h3 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.5rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .subsection h3::before {
            content: '';
            width: 4px;
            height: 24px;
            background: linear-gradient(135deg, var(--primary-color), var(--accent-color));
            border-radius: 2px;
        }
        
        .subsection p {
            color: var(--text-secondary);
            margin-bottom: 1rem;
            line-height: 1.7;
        }
        
        .subsection ul {
            color: var(--text-secondary);
            padding-left: 1.5rem;
        }
        
        .subsection li {
            margin-bottom: 0.5rem;
        }
        
        /* Tables */
        .clinical-table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: var(--spacing-md) 0;
            background: var(--bg-white);
            border-radius: var(--border-radius);
            overflow: hidden;
            box-shadow: var(--shadow-sm);
            border: 1px solid #e2e8f0;
        }
        
        .clinical-table th {
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: var(--spacing-md);
            text-align: left;
            font-weight: 600;
            font-size: 0.95rem;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        .clinical-table td {
            padding: var(--spacing-md);
            border-bottom: 1px solid #f1f5f9;
            transition: all 0.3s ease;
            color: var(--text-primary);
        }
        
        .clinical-table tbody tr:hover {
            background: #f8fafc;
        }
        
        .clinical-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Pathway diagrams */
        .pathway-diagram {
            background: var(--bg-white);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .pathway-diagram h4 {
            color: var(--text-primary);
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            text-align: center;
        }
        
        /* Enzyme boxes */
        .enzyme-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--primary-color), var(--secondary-color));
            color: white;
            padding: 12px 20px;
            margin: 6px;
            border-radius: 12px;
            font-weight: 600;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .enzyme-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        .enzyme-box.defect {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        @keyframes pulseGlow {
            0%, 100% {
                transform: scale(1);
                box-shadow: var(--shadow-sm);
            }
            50% {
                transform: scale(1.02);
                box-shadow: var(--shadow-md);
            }
        }
        
        .arrow {
            display: inline-block;
            margin: 0 var(--spacing-sm);
            font-size: 1.8rem;
            color: var(--primary-color);
            transition: all 0.3s ease;
        }
        
        .arrow:hover {
            transform: scale(1.2);
            color: var(--accent-color);
        }
        
        /* Highlight boxes */
        .highlight-box {
            background: linear-gradient(135deg, #fef3c7, #fde68a);
            border: 2px solid var(--warning-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            position: relative;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box::before {
            content: '‚ö†Ô∏è';
            position: absolute;
            top: -12px;
            left: 24px;
            background: linear-gradient(135deg, var(--warning-color), #fbbf24);
            padding: 8px 12px;
            border-radius: 50%;
            font-size: 1.2rem;
            box-shadow: var(--shadow-sm);
        }
        
        .highlight-box h4 {
            color: #92400e;
            margin-bottom: var(--spacing-sm);
            margin-top: var(--spacing-sm);
            font-weight: 600;
        }
        
        .highlight-box p, .highlight-box ul, .highlight-box li {
            color: #92400e;
        }
        
        /* Case study boxes */
        .case-study {
            background: linear-gradient(135deg, #ecfdf5, #d1fae5);
            border: 2px solid var(--success-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .case-study h4 {
            color: #065f46;
            margin-bottom: var(--spacing-md);
            font-size: 1.3rem;
            font-weight: 600;
            display: flex;
            align-items: center;
            gap: var(--spacing-xs);
        }
        
        .case-study p, .case-study ul, .case-study li {
            color: #065f46;
        }
        
        /* Metabolite boxes */
        .metabolite-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--accent-color), #0ea5e9);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .metabolite-box:hover {
            transform: translateY(-2px) scale(1.05);
            box-shadow: var(--shadow-md);
        }
        
        /* Hormone boxes for CAH */
        .hormone-box {
            display: inline-block;
            background: linear-gradient(135deg, var(--secondary-color), #be185d);
            color: white;
            padding: 10px 16px;
            margin: 4px;
            border-radius: 8px;
            font-size: 0.9rem;
            font-weight: 500;
            transition: all 0.3s ease;
            box-shadow: var(--shadow-sm);
        }
        
        .hormone-box.elevated {
            background: linear-gradient(135deg, var(--danger-color), #dc2626);
            animation: pulseGlow 2s infinite;
        }
        
        .hormone-box.decreased {
            background: linear-gradient(135deg, #6b7280, #4b5563);
        }
        
        /* Buttons */
        .next-step {
            text-align: center;
            margin-top: var(--spacing-xl);
        }
        
        .next-btn {
            background: linear-gradient(135deg, var(--success-color), var(--accent-color));
            color: white;
            border: none;
            padding: 18px 36px;
            border-radius: 50px;
            cursor: pointer;
            font-size: 16px;
            font-weight: 600;
            transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
            box-shadow: var(--shadow-md);
            text-transform: uppercase;
            letter-spacing: 1px;
        }
        
        .next-btn:hover {
            transform: translateY(-4px) scale(1.05);
            box-shadow: var(--shadow-lg);
        }
        
        .part-info {
            background: linear-gradient(135deg, #eff6ff, #dbeafe);
            border: 2px solid var(--info-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-md);
            margin-bottom: var(--spacing-lg);
            text-align: center;
            box-shadow: var(--shadow-sm);
        }
        
        .part-info h3 {
            color: var(--info-color);
            margin-bottom: var(--spacing-sm);
        }
        
        .part-info p {
            color: var(--text-secondary);
        }
        
        /* Special pathway styling */
        .desmosterol-pathway {
            background: linear-gradient(135deg, #f0f9ff, #e0f2fe);
            border: 2px solid var(--accent-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        .steroid-pathway {
            background: linear-gradient(135deg, #fdf4ff, #fae8ff);
            border: 2px solid var(--primary-color);
            border-radius: var(--border-radius);
            padding: var(--spacing-lg);
            margin: var(--spacing-md) 0;
            box-shadow: var(--shadow-sm);
        }
        
        /* Responsive design */
        @media (max-width: 768px) {
            .container {
                padding: var(--spacing-sm);
            }
            
            .header h1 {
                font-size: 2.5rem;
            }
            
            .navigation {
                flex-direction: column;
            }
            
            .nav-btn {
                width: 100%;
                text-align: center;
            }
            
            .content-section {
                padding: var(--spacing-md);
            }
            
            .section-title {
                font-size: 2rem;
            }
        }
        
        /* Animation stagger */
        .subsection {
            animation: fadeInStagger 0.6s ease-out both;
        }
        
        @keyframes fadeInStagger {
            from {
                opacity: 0;
                transform: translateY(20px);
            }
            to {
                opacity: 1;
                transform: translateY(0);
            }
        }
        
        .subsection:nth-child(1) { animation-delay: 0.1s; }
        .subsection:nth-child(2) { animation-delay: 0.2s; }
        .subsection:nth-child(3) { animation-delay: 0.3s; }
        .subsection:nth-child(4) { animation-delay: 0.4s; }
        .subsection:nth-child(5) { animation-delay: 0.5s; }
    </style>
</head>
<body>
    <div class="container">
        <div class="header">
            <h1>üß¨ Cholesterin-/Steroid-Biosynthese</h1>
            <p>Teil 2A: Desmosterolosis & 21-Hydroxylase CAH</p>
            <div class="progress-container">
                <div class="progress-fill" id="progressBar" style="width: 0%"></div>
            </div>
        </div>

        <div class="part-info">
            <h3>üìö Lerneinheit Teil 2A</h3>
            <p>Dieser Teil behandelt Desmosterolosis und die h√§ufigste Form der kongenitalen Nebennierenhyperplasie (21-Hydroxylase-Mangel) mit allen klinischen Details.</p>
        </div>

        <div class="navigation">
            <button class="nav-btn active" onclick="showSection('desmosterolosis')">1. Desmosterolosis</button>
            <button class="nav-btn" onclick="showSection('cah21-grundlagen')">2. CAH 21-OHD Grundlagen</button>
            <button class="nav-btn" onclick="showSection('cah21-klinik')">3. Klinik & Diagnostik</button>
            <button class="nav-btn" onclick="showSection('cah21-therapie')">4. Therapie & Management</button>
        </div>

        <!-- Desmosterolosis -->
        <div class="content-section active" id="desmosterolosis">
            <h2 class="section-title">üíé Desmosterolosis</h2>

            <div class="subsection">
                <h3>Definition und Epidemiologie</h3>
                <div class="case-study">
                    <h4>üî¨ Krankheitsdefinition</h4>
                    <p><strong>Desmosterolosis</strong> ist eine ultra-seltene autosomal-rezessive St√∂rung der terminalen Cholesterin-Biosynthese durch Defekt der Desmosterol-Reduktase (DHCR24).</p>
                    
                    <p><strong>Epidemiologie:</strong></p>
                    <ul>
                        <li><strong>Pr√§valenz:</strong> < 30 bekannte F√§lle weltweit</li>
                        <li><strong>Inzidenz:</strong> Gesch√§tzt <1:1.000.000</li>
                        <li><strong>Geografische Verteilung:</strong> Sporadisch, keine ethnischen H√§ufungen</li>
                        <li><strong>Geschlechtsverteilung:</strong> M:F = 1:1</li>
                        <li><strong>Erstbeschreibung:</strong> 2007 (Waterham et al.)</li>
                    </ul>
                </div>

                <div class="desmosterol-pathway">
                    <h4>DHCR24-Enzym und Metabolismus</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div style="background: #f8fafc; padding: 15px; border-radius: 8px; text-align: center; width: 100%;">
                            <h5 style="color: #0891b2; margin-bottom: 10px;">Kandel-Russell Pathway (85% der Cholesterin-Synthese)</h5>
                        </div>
                        
                        <div style="display: flex; flex-direction: column; align-items: center; gap: 15px;">
                            <div class="metabolite-box">24,25-Dihydrolanosterol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">‚Üì</span>
                            <div class="metabolite-box">Desmosterol</div>
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">‚Üì</span>
                            
                            <div class="enzyme-box defect" style="font-size: 1.1em; padding: 15px 25px;">DHCR24 (DEFEKT)</div>
                            <div style="text-align: center; color: #ef4444; font-weight: 600;">24-Dehydrocholesterin Reduktase</div>
                            <div style="text-align: center; color: #ef4444; font-size: 0.9em;">NADPH + H‚Å∫ abh√§ngig</div>
                            
                            <span class="arrow" style="transform: rotate(90deg); color: #0891b2;">‚Üì</span>
                            <div class="metabolite-box" style="background: linear-gradient(135deg, #10b981, #059669); font-size: 1.1em; padding: 15px 25px;">Cholesterin ‚Üì</div>
                        </div>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Parameter</th>
                            <th>Gen</th>
                            <th>Protein</th>
                            <th>Lokalisation</th>
                            <th>Funktion</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>DHCR24</strong></td>
                            <td>DHCR24 (1p33)</td>
                            <td>24-Dehydrocholesterin Reduktase</td>
                            <td>ER-Membran</td>
                            <td>Œî24-Reduktion von Desmosterol</td>
                        </tr>
                        <tr>
                            <td><strong>Alternative Namen</strong></td>
                            <td>SELADIN-1</td>
                            <td>Selective Alzheimer Disease Indicator-1</td>
                            <td>Ubiquit√§r exprimiert</td>
                            <td>Neuroprotektive Wirkung?</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Klinisches Spektrum</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>System</th>
                            <th>H√§ufigkeit</th>
                            <th>Merkmale</th>
                            <th>Verlauf</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>ZNS</strong></td>
                            <td>100%</td>
                            <td>Mikrozephalie, ID, Krampfanf√§lle, Ataxie</td>
                            <td>Progressiv</td>
                        </tr>
                        <tr>
                            <td><strong>Wachstum</strong></td>
                            <td>90%</td>
                            <td>Intrauterine/postnatale Wachstumsretardierung</td>
                            <td>Persistierend</td>
                        </tr>
                        <tr>
                            <td><strong>Fazial</strong></td>
                            <td>80%</td>
                            <td>Subtile Dysmorphie, breite Nasenwurzel</td>
                            <td>Nicht-progressiv</td>
                        </tr>
                        <tr>
                            <td><strong>Extremit√§ten</strong></td>
                            <td>50%</td>
                            <td>Brachydaktylie, Klinodaktylie</td>
                            <td>Statisch</td>
                        </tr>
                        <tr>
                            <td><strong>Ophthalmologisch</strong></td>
                            <td>60%</td>
                            <td>Katarakt, Strabismus</td>
                            <td>Kann progressiv sein</td>
                        </tr>
                        <tr>
                            <td><strong>Kardiovaskul√§r</strong></td>
                            <td>30%</td>
                            <td>Angeborene Herzfehler (meist mild)</td>
                            <td>Statisch</td>
                        </tr>
                    </tbody>
                </table>

                <div class="highlight-box">
                    <h4>Besonderheiten gegen√ºber SLOS</h4>
                    <p><strong>Wichtige Unterschiede:</strong></p>
                    <ul>
                        <li><strong>Desmosterol vs. 7-DHC:</strong> Weniger toxisch, teilweise funktional</li>
                        <li><strong>Kandel-Russell vs. Bloch:</strong> Beeintr√§chtigt 85% vs. 15% der Cholesterin-Synthese</li>
                        <li><strong>Entwicklungsdefekte:</strong> Weniger schwer, sp√§tere Manifestation</li>
                        <li><strong>Neurodegeneration:</strong> Progressiv, postnatale Verschlechterung</li>
                        <li><strong>Lebenserwartung:</strong> L√§nger als schwere SLOS-Formen</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Diagnostik und Therapie</h3>
                <div class="pathway-diagram">
                    <h4>Biochemische Diagnostik</h4>
                    
                    <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 20px; border-radius: 10px; margin: 20px 0; border: 2px solid #3b82f6;">
                        <p><strong>Sterol-Profil Analyse:</strong></p>
                        <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(200px, 1fr)); gap: 15px; margin: 15px 0;">
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #ef4444, #dc2626); margin: 0 0 10px 0; width: 100%;">Desmosterol ‚Üë‚Üë</div>
                                <p style="font-size: 0.9em;">Normal: <0.5 mg/dl<br>Desmosterolosis: 5-20 mg/dl</p>
                            </div>
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #059669, #047857); margin: 0 0 10px 0; width: 100%;">Cholesterin ‚Üì</div>
                                <p style="font-size: 0.9em;">Meist moderat reduziert<br>50-120 mg/dl</p>
                            </div>
                            <div style="text-align: center;">
                                <div class="metabolite-box" style="background: linear-gradient(135deg, #0891b2, #0e7490); margin: 0 0 10px 0; width: 100%;">7-DHC normal</div>
                                <p style="font-size: 0.9em;">Wichtige DD zu SLOS<br><0.5 mg/dl</p>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>üíä Therapeutische Ans√§tze</h4>
                    <p><strong>Cholesterin-Supplementation:</strong></p>
                    <ul>
                        <li><strong>Dosierung:</strong> 50-100 mg/kg/d oral</li>
                        <li><strong>Wirksamkeit:</strong> Begrenzt, da Desmosterol teilweise funktional</li>
                        <li><strong>Monitoring:</strong> Sterol-Profil alle 6 Monate</li>
                    </ul>
                    
                    <p><strong>Symptomatische Therapie:</strong></p>
                    <ul>
                        <li><strong>Antiepileptika:</strong> Bei Krampfanf√§llen</li>
                        <li><strong>Physiotherapie:</strong> Bei Ataxie/Spastik</li>
                        <li><strong>Ophthalmologie:</strong> Kataraktchirurgie</li>
                        <li><strong>Entwicklungsf√∂rderung:</strong> Multidisziplin√§r</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah21-grundlagen')">Weiter zu CAH 21-OHD ‚Üí</button>
            </div>
        </div>

        <!-- CAH 21-OHD Grundlagen -->
        <div class="content-section" id="cah21-grundlagen">
            <h2 class="section-title">üî• 21-Hydroxylase Mangel - Grundlagen</h2>

            <div class="subsection">
                <h3>Definition und Epidemiologie</h3>
                <div class="case-study">
                    <h4>üî¨ Kongenitale Nebennierenhyperplasie (CAH)</h4>
                    <p><strong>21-Hydroxylase-Mangel</strong> ist die h√§ufigste Form der kongenitalen Nebennierenhyperplasie, verursacht durch Defekte im CYP21A2-Gen.</p>
                    
                    <p><strong>Epidemiologie:</strong></p>
                    <ul>
                        <li><strong>Gesamtinzidenz:</strong> 1:10.000 - 1:15.000 Geburten</li>
                        <li><strong>Klassische Form:</strong> 1:15.000 (75% Salzverlust, 25% einfach virilisierend)</li>
                        <li><strong>Nicht-klassische Form:</strong> 1:1.000 (sehr h√§ufig!)</li>
                        <li><strong>Ethnische Variationen:</strong> H√∂her bei Aschkenasi-Juden (1:27 Tr√§ger)</li>
                        <li><strong>Geschlechtsverteilung:</strong> M:F = 1:1 (autosomal-rezessiv)</li>
                    </ul>
                </div>

                <div class="steroid-pathway">
                    <h4>Steroidogenese und 21-Hydroxylase</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 20px; margin: 20px 0;">
                        <div class="metabolite-box" style="background: linear-gradient(135deg, #8b5cf6, #7c3aed); font-size: 1.1em; padding: 15px 25px;">Cholesterin</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">‚Üì</span>
                        
                        <div class="enzyme-box">CYP11A1 (Side-chain cleavage)</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">‚Üì</span>
                        
                        <div class="metabolite-box" style="background: linear-gradient(135deg, #ec4899, #be185d);">Pregnenolon</div>
                        <span class="arrow" style="transform: rotate(90deg); color: #8b5cf6;">‚Üì</span>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; width: 100%;">
                            <div style="text-align: center;">
                                <h5 style="color: #3b82f6; margin-bottom: 15px;">Kortisol-Synthese</h5>
                                <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                    <div class="metabolite-box">17-OH-Pregnenolon</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="metabolite-box">17-OH-Progesteron</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="enzyme-box defect">CYP21A2 (DEFEKT)</div>
                                    <div style="font-weight: 600; color: #ef4444; font-size: 0.9em;">21-Hydroxylase</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="hormone-box decreased">11-Deoxykortisol ‚Üì</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="hormone-box decreased">Kortisol ‚Üì‚Üì</div>
                                </div>
                            </div>
                            
                            <div style="text-align: center;">
                                <h5 style="color: #f59e0b; margin-bottom: 15px;">Mineralokortikoid-Synthese</h5>
                                <div style="display: flex; flex-direction: column; align-items: center; gap: 10px;">
                                    <div class="metabolite-box">Progesteron</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="enzyme-box defect">CYP21A2 (DEFEKT)</div>
                                    <div style="font-weight: 600; color: #ef4444; font-size: 0.9em;">21-Hydroxylase</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="hormone-box decreased">11-Deoxykortikosteron ‚Üì</div>
                                    <span class="arrow" style="transform: rotate(90deg); font-size: 1.2em;">‚Üì</span>
                                    <div class="hormone-box decreased">Aldosteron ‚Üì‚Üì</div>
                                </div>
                            </div>
                        </div>
                        
                        <div style="margin-top: 20px; text-align: center;">
                            <h5 style="color: #ef4444; margin-bottom: 10px;">üîÑ Kompensatorische Androgen-Produktion</h5>
                            <div class="hormone-box elevated">17-OH-Progesteron ‚Üë‚Üë‚Üë</div>
                            <span class="arrow">‚Üí</span>
                            <div class="hormone-box elevated">Androstendion ‚Üë‚Üë</div>
                            <span class="arrow">‚Üí</span>
                            <div class="hormone-box elevated">Testosteron ‚Üë‚Üë</div>
                        </div>
                    </div>
                </div>
            </div>

            <div class="subsection">
                <h3>Molekulargenetik</h3>
                <div class="pathway-diagram">
                    <h4>CYP21A2-Gen und Pseudogen</h4>
                    
                    <div style="background: #f8fafc; padding: 20px; border-radius: 12px; margin: 20px 0; border: 1px solid #e2e8f0;">
                        <p><strong>Komplexe Genstruktur:</strong></p>
                        <ul>
                            <li><strong>Lokalisation:</strong> Chromosom 6p21.3 (HLA-Komplex)</li>
                            <li><strong>Tandem-Arrangement:</strong> CYP21A2 (aktiv) und CYP21A1P (Pseudogen)</li>
                            <li><strong>TNXA/TNXB:</strong> Benachbarte Gene (Tenascin X)</li>
                            <li><strong>Rekombinations-Hotspot:</strong> H√§ufige Genmutationen durch unequal crossing over</li>
                        </ul>
                    </div>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Mutationstyp</th>
                            <th>H√§ufigkeit (%)</th>
                            <th>Enzymaktivit√§t</th>
                            <th>Ph√§notyp</th>
                            <th>Besonderheiten</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Large gene deletion</strong></td>
                            <td>20%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>Komplett fehlend</td>
                        </tr>
                        <tr>
                            <td><strong>I2-Splice (c.293-13A>G)</strong></td>
                            <td>25%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>H√§ufigste SW-Mutation</td>
                        </tr>
                        <tr>
                            <td><strong>8bp-deletion (c.329_336del)</strong></td>
                            <td>10%</td>
                            <td>0%</td>
                            <td>SW</td>
                            <td>Frameshift</td>
                        </tr>
                        <tr>
                            <td><strong>I172N (c.515T>A)</strong></td>
                            <td>15%</td>
                            <td>1-2%</td>
                            <td>SV</td>
                            <td>Temperatur-labil</td>
                        </tr>
                        <tr>
                            <td><strong>V281L (c.842G>T)</strong></td>
                            <td>20%</td>
                            <td>20-50%</td>
                            <td>NC</td>
                            <td>H√§ufigste NC-Mutation</td>
                        </tr>
                        <tr>
                            <td><strong>P30L (c.89C>T)</strong></td>
                            <td>5%</td>
                            <td>30-60%</td>
                            <td>NC</td>
                            <td>Mild</td>
                        </tr>
                    </tbody>
                </table>

                <div class="highlight-box">
                    <h4>Genotyp-Ph√§notyp Korrelationen</h4>
                    <p><strong>Vorhersagbare Muster:</strong></p>
                    <ul>
                        <li><strong>Null/Null Mutationen:</strong> Immer Salzverlust-Form</li>
                        <li><strong>I172N compound heterozygot:</strong> Meist einfach virilisierend</li>
                        <li><strong>V281L homozygot:</strong> Typisch nicht-klassische Form</li>
                        <li><strong>Severe/Mild Kombinationen:</strong> Intermedi√§re Ph√§notypen</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah21-klinik')">Weiter zu Klinik & Diagnostik ‚Üí</button>
            </div>
        </div>

        <!-- CAH 21-OHD Klinik & Diagnostik -->
        <div class="content-section" id="cah21-klinik">
            <h2 class="section-title">ü©∫ Klinik & Diagnostik</h2>

            <div class="subsection">
                <h3>Klinische Formen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Form</th>
                            <th>Enzymaktivit√§t</th>
                            <th>17-OHP (ng/ml)</th>
                            <th>Klinische Merkmale</th>
                            <th>Manifestationsalter</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Salzverlust (SW)</strong></td>
                            <td>0-1%</td>
                            <td>>20.000</td>
                            <td>Virilisierung + Salzverlust</td>
                            <td>Neonatal (1-3 Wochen)</td>
                        </tr>
                        <tr>
                            <td><strong>Einfach virilisierend (SV)</strong></td>
                            <td>1-5%</td>
                            <td>3.000-20.000</td>
                            <td>Virilisierung ohne Salzverlust</td>
                            <td>Neonatal/fr√ºhe Kindheit</td>
                        </tr>
                        <tr>
                            <td><strong>Nicht-klassisch (NC)</strong></td>
                            <td>5-50%</td>
                            <td>300-3.000</td>
                            <td>Milde Hyperandrogen√§mie</td>
                            <td>Pubert√§t/Erwachsenenalter</td>
                        </tr>
                        <tr>
                            <td><strong>Asymptomatisch</strong></td>
                            <td>>50%</td>
                            <td><300</td>
                            <td>Keine klinischen Symptome</td>
                            <td>Nie</td>
                        </tr>
                    </tbody>
                </table>

                <div class="case-study">
                    <h4>üë∂ Neonatale Pr√§sentation</h4>
                    <p><strong>Weibliche Neugeborene (klassische CAH):</strong></p>
                    <ul>
                        <li><strong>Ambige Genitalien:</strong> Virilisierung durch pr√§natale Androgen-Exposition</li>
                        <li><strong>Prader-Skala:</strong> Grad II-V (Klitorishypertrophie bis komplett m√§nnliches Erscheinungsbild)</li>
                        <li><strong>Interne Strukturen:</strong> Normal weiblich (Uterus, Ovarien)</li>
                        <li><strong>Diagnose:</strong> Meist bei Geburt durch Genitaluntersuchung</li>
                    </ul>
                    
                    <p><strong>M√§nnliche Neugeborene:</strong></p>
                    <ul>
                        <li><strong>Genitalien:</strong> Normal oder leichte Hyperpigmentierung</li>
                        <li><strong>Salzverlustkrise:</strong> Oft erste Manifestation (Woche 1-3)</li>
                        <li><strong>Diagnose:</strong> Oft verz√∂gert, erst bei Salzverlustkrise</li>
                        <li><strong>Mortalit√§t:</strong> H√∂her durch sp√§te Diagnose</li>
                    </ul>
                    
                    <p><strong>Salzverlustkrise (75% der klassischen F√§lle):</strong></p>
                    <ul>
                        <li><strong>Zeitpunkt:</strong> Meist Tag 5-15 des Lebens</li>
                        <li><strong>Symptome:</strong> Erbrechen, Dehydratation, Lethargie</li>
                        <li><strong>Labor:</strong> Hyponatri√§mie (<130 mmol/l), Hyperkali√§mie (>7 mmol/l)</li>
                        <li><strong>Notfall:</strong> Lebensbedrohlich ohne Behandlung</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Diagnostik</h3>
                <div class="pathway-diagram">
                    <h4>Diagnostischer Algorithmus</h4>
                    
                    <div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">
                        <div style="background: #fef3c7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #f59e0b;">
                            <strong>Verdacht auf CAH</strong><br>
                            Ambige Genitalien / Salzverlustkrise / Hyperandrogen√§mie
                        </div>
                        <span class="arrow" style="transform: rotate(90deg); color: #f59e0b;">‚Üì</span>
                        
                        <div style="background: #dbeafe; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #3b82f6;">
                            <strong>17-OH-Progesteron (n√ºchtern, 8 Uhr)</strong><br>
                            Screening-Parameter
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 1fr 1fr 1fr; gap: 15px; width: 100%;">
                            <div style="background: #dcfce7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #22c55e;">
                                <strong>>300 ng/ml</strong><br>
                                Klassische CAH sicher
                            </div>
                            <div style="background: #fef3c7; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #f59e0b;">
                                <strong>30-300 ng/ml</strong><br>
                                ACTH-Test
                            </div>
                            <div style="background: #fee2e2; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #ef4444;">
                                <strong><30 ng/ml</strong><br>
                                CAH unwahrscheinlich
                            </div>
                        </div>
                        <span class="arrow" style="transform: rotate(90deg); color: #22c55e;">‚Üì</span>
                        
                        <div style="background: #ecfdf5; padding: 15px; border-radius: 8px; text-align: center; border: 2px solid #10b981;">
                            <strong>Molekulargenetik + Therapie</strong><br>
                            CYP21A2 Sequenzierung + MLPA
                        </div>
                    </div>
                </div>

                <div class="case-study">
                    <h4>‚ö° ACTH-Stimulationstest</h4>
                    <p><strong>Protokoll:</strong></p>
                    <ul>
                        <li><strong>Dosierung:</strong> 250 Œºg ACTH (Synacthen) i.v./i.m.</li>
                        <li><strong>Zeitpunkte:</strong> 0, 30, 60 Minuten</li>
                        <li><strong>Parameter:</strong> 17-OHP, Kortisol, Androstendion</li>
                        <li><strong>Interpretation:</strong> 60-min 17-OHP >10.000 ng/ml = klassische CAH</li>
                    </ul>
                    
                    <p><strong>Neugeborenenscreening:</strong></p>
                    <ul>
                        <li><strong>Parameter:</strong> 17-OHP aus Trockenblut</li>
                        <li><strong>Timing:</strong> 36-72 Stunden postnatal</li>
                        <li><strong>Cut-off:</strong> Gewichts-adjustiert (Fr√ºhgeborene h√∂her)</li>
                        <li><strong>Falsch-positive:</strong> Stress, Fr√ºhgeburtlichkeit</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Nicht-klassische CAH</h3>
                <div class="highlight-box">
                    <h4>H√§ufigste Form - oft √ºbersehen!</h4>
                    <p><strong>Klinische Manifestationen bei Frauen:</strong></p>
                    <ul>
                        <li><strong>Hirsutismus:</strong> 80% der Patientinnen</li>
                        <li><strong>Oligomenorrhoe/Amenorrhoe:</strong> 60%</li>
                        <li><strong>Alopezie (m√§nnlicher Typ):</strong> 40%</li>
                        <li><strong>Akne (therapieresistent):</strong> 70%</li>
                        <li><strong>Infertilit√§t:</strong> 20-30%</li>
                        <li><strong>Reduzierte finale Gr√∂√üe:</strong> Bei sp√§tem Therapiebeginn</li>
                    </ul>
                    
                    <p><strong>Bei M√§nnern:</strong></p>
                    <ul>
                        <li><strong>Oft asymptomatisch</strong> bis auf reduzierte Gr√∂√üe</li>
                        <li><strong>Oligospermie:</strong> Gelegentlich</li>
                        <li><strong>Fr√ºhe Pubarche:</strong> Als Hinweis</li>
                        <li><strong>Akne:</strong> Schwer therapierbar</li>
                    </ul>
                    
                    <p><strong>Differentialdiagnose:</strong></p>
                    <ul>
                        <li><strong>PCOS:</strong> H√§ufigste DD bei Frauen</li>
                        <li><strong>Idiopathischer Hirsutismus:</strong> 17-OHP normal</li>
                        <li><strong>Androgen-produzierende Tumoren:</strong> Akuter Beginn</li>
                        <li><strong>Medikamente:</strong> Anabolika, Danazol</li>
                    </ul>
                </div>
            </div>

            <div class="next-step">
                <button class="next-btn" onclick="showSection('cah21-therapie')">Weiter zu Therapie & Management ‚Üí</button>
            </div>
        </div>

        <!-- CAH 21-OHD Therapie -->
        <div class="content-section" id="cah21-therapie">
            <h2 class="section-title">üíä Therapie & Management</h2>

            <div class="subsection">
                <h3>Akuttherapie der Salzverlustkrise</h3>
                <div class="case-study">
                    <h4>üö® Notfallprotokoll</h4>
                    <p><strong>Sofortma√ünahmen (erste 30 Minuten):</strong></p>
                    <ul>
                        <li><strong>Volumenexpansion:</strong> 20 ml/kg NaCl 0.9% i.v. √ºber 30 min</li>
                        <li><strong>Hydrocortison:</strong> 100 mg/m¬≤ KOF i.v. (max. 100 mg)</li>
                        <li><strong>Glukose:</strong> Bei Hypoglyk√§mie 2 ml/kg Glukose 10%</li>
                        <li><strong>Monitoring:</strong> RR, Herzfrequenz, Elektrolyte</li>
                    </ul>
                    
                    <p><strong>Erhaltungstherapie (nach Stabilisierung):</strong></p>
                    <ul>
                        <li><strong>Hydrocortison:</strong> 100-150 mg/m¬≤/d in 3-4 Dosen</li>
                        <li><strong>Fludrocortison:</strong> 0.1-0.3 mg/d (0.05-0.2 mg bei Kindern)</li>
                        <li><strong>NaCl-Supplementation:</strong> 1-3 g/d bei S√§uglingen</li>
                        <li><strong>Fl√ºssigkeit:</strong> Altersentsprechend, bei Verlusten ersetzen</li>
                    </ul>
                </div>

                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Altersgruppe</th>
                            <th>Hydrocortison (mg/m¬≤/d)</th>
                            <th>Fludrocortison (mg/d)</th>
                            <th>Monitoring-Parameter</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>0-2 Jahre</strong></td>
                            <td>15-20</td>
                            <td>0.05-0.15</td>
                            <td>17-OHP, PRA, Elektrolyte</td>
                        </tr>
                        <tr>
                            <td><strong>2-10 Jahre</strong></td>
                            <td>12-18</td>
                            <td>0.05-0.2</td>
                            <td>17-OHP, PRA, Wachstum</td>
                        </tr>
                        <tr>
                            <td><strong>Pubert√§t</strong></td>
                            <td>10-15</td>
                            <td>0.05-0.2</td>
                            <td>17-OHP, PRA, Tanner</td>
                        </tr>
                        <tr>
                            <td><strong>Erwachsene</strong></td>
                            <td>8-12</td>
                            <td>0.05-0.2</td>
                            <td>17-OHP, PRA, Androgene</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="subsection">
                <h3>Langzeit-Management</h3>
                <div class="pathway-diagram">
                    <h4>Therapieziele und Monitoring</h4>
                    
                    <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 20px; margin: 20px 0;">
                        <div style="background: linear-gradient(135deg, #ecfdf5, #d1fae5); padding: 20px; border-radius: 8px; border: 2px solid #22c55e;">
                            <h5 style="color: #16a34a; margin-bottom: 15px;">üéØ Therapieziele</h5>
                            <ul style="font-size: 0.9em; color: #16a34a;">
                                <li>Normales Wachstum und Entwicklung</li>
                                <li>Vermeidung von Salzverlusten</li>
                                <li>Suppression der Androgen-√úberproduktion</li>
                                <li>Erhaltung der Fertilit√§t</li>
                                <li>Minimierung der Cushing-Nebenwirkungen</li>
                                <li>Normale Lebensqualit√§t</li>
                            </ul>
                        </div>
                        
                        <div style="background: linear-gradient(135deg, #eff6ff, #dbeafe); padding: 20px; border-radius: 8px; border: 2px solid #3b82f6;">
                            <h5 style="color: #2563eb; margin-bottom: 15px;">üìä Monitoring-Parameter</h5>
                            <ul style="font-size: 0.9em; color: #2563eb;">
                                <li><strong>17-OHP:</strong> Ziel 100-1000 ng/ml</li>
                                <li><strong>Androstendion:</strong> Altersgerecht</li>
                                <li><strong>PRA:</strong> Oberer Normbereich</li>
                                <li><strong>Elektrolyte:</strong> Normal</li>
                                <li><strong>Wachstumskurve:</strong> Perzentilen</li>
                                <li><strong>Knochelalter:</strong> Chronologisches Alter ¬±1 Jahr</li>
                            </ul>
                        </div>
                    </div>
                </div>

                <div class="highlight-box">
                    <h4>Dosisanpassungen bei Stress</h4>
                    <p><strong>Stress-Dosierung Hydrocortison:</strong></p>
                    <ul>
                        <li><strong>Fieber >38.5¬∞C:</strong> Doppelte Tagesdosis f√ºr 2-3 Tage</li>
                        <li><strong>Erbrechen:</strong> Sofort i.v./i.m. Hydrocortison, dann doppelt</li>
                        <li><strong>Kleinere OPs:</strong> 50-75 mg/m¬≤ am OP-Tag</li>
                        <li><strong>Gr√∂√üere OPs:</strong> 100-150 mg/m¬≤ perioperativ</li>
                        <li><strong>Schwerer Stress:</strong> Bis 300 mg/m¬≤/d in schweren F√§llen</li>
                    </ul>
                    
                    <p><strong>Patientenschulung essentiell:</strong></p>
                    <ul>
                        <li><strong>Notfallausweis:</strong> Immer mitf√ºhren</li>
                        <li><strong>Stressdosis-Schema:</strong> Schriftliche Anleitung</li>
                        <li><strong>Notfall-Hydrocortison:</strong> Immer verf√ºgbar</li>
                        <li><strong>24h-Erreichbarkeit:</strong> Endokrinologe/P√§diatrie</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Spezielle Situationen</h3>
                <div class="case-study">
                    <h4>ü§± Schwangerschaft bei CAH</h4>
                    <p><strong>Pr√§konzeptionelle Planung:</strong></p>
                    <ul>
                        <li><strong>Optimale Einstellung:</strong> 17-OHP <1000 ng/ml</li>
                        <li><strong>Fols√§ure:</strong> 5 mg/d ab 4 Wochen vor Konzeption</li>
                        <li><strong>Genetische Beratung:</strong> 25% Wiederholungsrisiko</li>
                        <li><strong>Partnertestung:</strong> CYP21A2-Screening empfohlen</li>
                    </ul>
                    
                    <p><strong>Schwangerschafts-Management:</strong></p>
                    <ul>
                        <li><strong>Dexamethason:</strong> Wenn Fetus betroffen (ab 6. SSW)</li>
                        <li><strong>Pr√§nataldiagnostik:</strong> CVS (10-12 SSW) oder AC (15-18 SSW)</li>
                        <li><strong>Monitoring:</strong> 17-OHP alle 4-6 Wochen</li>
                        <li><strong>Geburt:</strong> Stress-Dosis Hydrocortison</li>
                    </ul>
                    
                    <p><strong>Postpartum:</strong></p>
                    <ul>
                        <li><strong>Stillen:</strong> M√∂glich unter Hydrocortison</li>
                        <li><strong>Neugeborenen-Screening:</strong> 17-OHP am 3. Tag</li>
                        <li><strong>Fr√ºhzeitige Betreuung:</strong> Bei auff√§lligen Genitalien</li>
                    </ul>
                </div>

                <div class="case-study">
                    <h4>‚öïÔ∏è Geschlechtszuordnung und DSD-Management</h4>
                    <p><strong>46,XX DSD bei CAH:</strong></p>
                    <ul>
                        <li><strong>Geschlechtszuordnung:</strong> Meist weiblich (>95%)</li>
                        <li><strong>Genitoplastik:</strong> Timing kontrovers (6-24 Monate vs. sp√§ter)</li>
                        <li><strong>Psychologische Betreuung:</strong> DSD-Team erforderlich</li>
                        <li><strong>Aufkl√§rung der Eltern:</strong> Umfassend und einf√ºhlsam</li>
                    </ul>
                    
                    <p><strong>Langzeit-Outcomes:</strong></p>
                    <ul>
                        <li><strong>Geschlechtsidentit√§t:</strong> >95% identifizieren sich weiblich</li>
                        <li><strong>Sexuelle Funktion:</strong> Meist normal bei ad√§quater Chirurgie</li>
                        <li><strong>Fertilit√§t:</strong> M√∂glich bei guter Hormonkontrolle</li>
                        <li><strong>Psychosoziale Entwicklung:</strong> Meist normal</li>
                    </ul>
                </div>
            </div>

            <div class="subsection">
                <h3>Langzeitprognose und Komplikationen</h3>
                <table class="clinical-table">
                    <thead>
                        <tr>
                            <th>Komplikation</th>
                            <th>Risikofaktor</th>
                            <th>Pr√§valenz</th>
                            <th>Pr√§vention</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Kleinwuchs</strong></td>
                            <td>√úberbehandlung mit GK</td>
                            <td>20-30%</td>
                            <td>Wachstumsmonitoring</td>
                        </tr>
                        <tr>
                            <td><strong>Osteoporose</strong></td>
                            <td>Chronische GK-√úberdosis</td>
                            <td>15-25%</td>
                            <td>Niedrigste effektive Dosis</td>
                        </tr>
                        <tr>
                            <td><strong>Metabolisches Syndrom</strong></td>
                            <td>GK-Nebenwirkungen</td>
                            <td>10-20%</td>
                            <td>Lifestyle, optimale Dosis</td>
                        </tr>
                        <tr>
                            <td><strong>Infertilit√§t</strong></td>
                            <td>Schlechte Kontrolle</td>
                            <td>10-15%</td>
                            <td>Optimale Hormoneinstellung</td>
                        </tr>
                        <tr>
                            <td><strong>Nebennierentumoren</strong></td>
                            <td>Chronische ACTH-Stimulation</td>
                            <td>5-10%</td>
                            <td>Ad√§quate Suppression</td>
                        </tr>
                    </tbody>
                </table>
            </div>

            <div class="next-step">
                <div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
                    <h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Teil 2A abgeschlossen!</h3>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben Desmosterolosis und 21-Hydroxylase CAH erfolgreich durchgearbeitet.</p>
                    <p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Als n√§chstes:</strong> Teil 2B mit anderen CAH-Formen und erweiterten Steroidogenese-St√∂rungen</p>
                    <button class="next-btn">Weiter zu Teil 2B ‚Üí</button>
                </div>
            </div>
        </div>
    </div>

    <script>
        let currentSection = 0;
        const sections = ['desmosterolosis', 'cah21-grundlagen', 'cah21-klinik', 'cah21-therapie'];

        function showSection(sectionId) {
            // Hide all sections
            const allSections = document.querySelectorAll('.content-section');
            allSections.forEach(section => section.classList.remove('active'));

            // Remove active class from all nav buttons
            const allButtons = document.querySelectorAll('.nav-btn');
            allButtons.forEach(btn => btn.classList.remove('active'));

            // Show selected section
            document.getElementById(sectionId).classList.add('active');

            // Highlight active nav button
            event.target.classList.add('active');

            // Update progress bar
            currentSection = sections.indexOf(sectionId);
            const progress = ((currentSection + 1) / sections.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';

            // Scroll to top
            window.scrollTo(0, 0);
        }

        // Initialize progress bar
        document.getElementById('progressBar').style.width = '25%';
    </script>
</body>
</html>
